The Amplified Sciences team is committed to providing healthcare providers with innovative diagnostic tools that enable earlier detection, risk stratification and monitoring of challenging diseases.
PanCystPro is now available in our CLIA lab through an Early Access Program. This test assists clinicians in the risk stratification of patients diagnosed with pancreatic cystic lesions (PCL). This multianalyte panel is powered by a proprietary algorithm.
In testing among several clinical cohorts, the assay provides the advantages of increased accuracy, high negative predictive value, a robust panel of biomarkers including the measurement of important protease activity, and a significantly reduced volume of pancreatic cyst fluid required.
